Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data

Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer 
Trials Data 
NEW YORK, NY -- (Marketwired) -- 08/28/13 --  As Nuvilex, Inc.
(OTCQB: NVLX) continues to methodically build its brand as a
biotechnology firm ahead of its future Phase III clinical trials for
the treatment of advanced, inoperable pancreatic cancer, it looks on
while one more big pharmaceutical company produces inferior data to
its own. This time it's Incyte Corporation, a $5.5 billion market cap
company that just enjoyed a more than $10 rise in its share price to
over $37/share after positive data was announced for its mid-phase
pancreatic cancer clinical trials. 
Another clinical trial, another big pharmaceutical company, and
another positive outcome for Nuvilex shareholders as the company once
again produces better clinical trials data than the competition.
Incyte investors rewarded the company's work with a 30% increase in
its share price.  
So, what is Nuvilex truly worth considering it's currently priced at
less than $0.135 per share and its mid-phase data is better than any
data produced by Incyte, Celgene, Infinity Pharmaceuticals, and even
Eli Lilly, whose pancreatic cancer drug, Gemzar (gemcitabine), is the
industry's "gold standard" and the only drug approved by the FDA as a
single agent for the treatment of advanced, inoperable pancreatic
cancer. 
In commenting on Incyte's clinical trial results, Nuvilex's COO, Dr.
Gerry Crabtree, stated, "The excitement engendered within the
investment community upon publication of Incyte's mid-phase clinical
trial data, as manifested by a 30% increase in that company's share
price, serves to add impetus to all of us at Nuvilex in our pursuit
of further clinical studies with our pancreatic cancer treatment. The
fact that data such as that from Incyte's trial do not appear to
surpass that obtained in our mid-phase clinical trials, only
reinforces our belief that in the future, our treatment will help
those who suffer from advanced pancreatic cancer, one of the
deadliest and most difficult-to-treat forms of the disease." 
Let's compare Nuvilex to the latest company releasing pancreatic
cancer clinical trials results: 
Continue Reading at: www.stockmarketmediagroup.com/features 
About Stock Market Media Group  
Stock Market Media Group is a full service Investment Relations firm
specializing in Research and Content Development. It offers a
platform for CEOs to tell their story through the media with Reports,
CEO Interviews and Feature Articles. For more information:
www.stockmarketmediagroup.com  
Contact:
Stock Market Media
info@stockmarketmediagroup.com